2 Information about sarilumab

Marketing authorisation

Sarilumab (Kevzara, Sanofi) has a marketing authorisation in the UK for the 'treatment of moderately to severely active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs.' Sarilumab can be given as monotherapy or in combination with methotrexate.

Price

The list price per pre-filled pen or syringe of 150 mg or 200 mg of sarilumab is £456.13.

The average cost per patient per year is estimated at £11,900 based on the list price.

The company has agreed a patient access scheme with the Department of Health. This scheme provides a simple discount to the list price of sarilumab, with the discount applied at the point of purchase or invoice. The level of the discount is commercial in confidence. The Department of Health considered that this patient access scheme does not constitute an excessive administrative burden on the NHS.